CA2398163C - Therapeutic morpholino-substituted compounds - Google Patents

Therapeutic morpholino-substituted compounds Download PDF

Info

Publication number
CA2398163C
CA2398163C CA2398163A CA2398163A CA2398163C CA 2398163 C CA2398163 C CA 2398163C CA 2398163 A CA2398163 A CA 2398163A CA 2398163 A CA2398163 A CA 2398163A CA 2398163 C CA2398163 C CA 2398163C
Authority
CA
Canada
Prior art keywords
tgx
chr3
aryl
heteroaryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2398163A
Other languages
English (en)
French (fr)
Other versions
CA2398163A1 (en
Inventor
Alan D. Robertson
Shaun Jackson
Vijaya Kenche
Cindy Yaip
Hishani Prabaharan
Phil Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA2398163A1 publication Critical patent/CA2398163A1/en
Application granted granted Critical
Publication of CA2398163C publication Critical patent/CA2398163C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA2398163A 2000-01-24 2001-01-24 Therapeutic morpholino-substituted compounds Expired - Fee Related CA2398163C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17735100P 2000-01-24 2000-01-24
US60/177,351 2000-01-24
US22582600P 2000-08-17 2000-08-17
US60/225,826 2000-08-17
PCT/IB2001/000079 WO2001053266A1 (en) 2000-01-24 2001-01-24 Therapeutic morpholino-substituted compounds

Publications (2)

Publication Number Publication Date
CA2398163A1 CA2398163A1 (en) 2001-07-26
CA2398163C true CA2398163C (en) 2011-02-22

Family

ID=26873182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2398163A Expired - Fee Related CA2398163C (en) 2000-01-24 2001-01-24 Therapeutic morpholino-substituted compounds

Country Status (14)

Country Link
US (4) US6977255B2 (enExample)
EP (2) EP1257537B1 (enExample)
JP (1) JP4820518B2 (enExample)
CN (3) CN1891693A (enExample)
AT (2) ATE363471T1 (enExample)
AU (2) AU2001230426C1 (enExample)
CA (1) CA2398163C (enExample)
CY (1) CY1108023T1 (enExample)
DE (1) DE60128655T2 (enExample)
DK (1) DK1257537T3 (enExample)
ES (1) ES2286093T3 (enExample)
NZ (1) NZ520300A (enExample)
PT (1) PT1257537E (enExample)
WO (1) WO2001053266A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB2405870B (en) * 2001-08-14 2005-07-06 Cancer Rec Tech Ltd DNA-PK inhibitors
CN1551766A (zh) * 2001-09-05 2004-12-01 ������������ʽ���� 淋巴细胞活化抑制剂和自身免疫性疾病治疗剂
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
EP1537102A4 (en) * 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
CN101260104A (zh) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
BR0316386A (pt) 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
WO2004089925A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
MXPA05013210A (es) * 2003-06-05 2006-03-09 Warner Lambert Co Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2004108709A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents
KR20060066722A (ko) 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 ａｔｍ억제제로서의 이의 용도
BRPI0414171A (pt) * 2003-09-04 2006-10-31 Warner Lambert Co benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos
ATE365732T1 (de) * 2003-10-31 2007-07-15 Warner Lambert Co Pyrimidine als inhibitoren von phosphoinositid-3- kinasen (pi3k)
AU2005228845A1 (en) * 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
CN1300163C (zh) * 2004-06-23 2007-02-14 南京大学 3－羟基色原酮糖苷及其制法和用途
RU2408596C2 (ru) 2004-09-20 2011-01-10 Кудос Фармасьютикалс Лимитед Ингибиторы днк-пк
JP2008529995A (ja) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
WO2007127366A2 (en) 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
JP5415942B2 (ja) * 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤
WO2008102932A1 (en) * 2007-02-21 2008-08-28 Biobud Co., Ltd. Compositions for treating hyperproliferative vascular disorders and cancers
EP2157092A4 (en) 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
EP2154965A4 (en) * 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
JP2011510071A (ja) * 2008-01-25 2011-03-31 アストラゼネカ アクチボラグ 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６
EP2262366A4 (en) * 2008-04-18 2012-02-22 Shenogen Pharma Group Ltd COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
PL2448940T3 (pl) 2009-07-02 2014-10-31 Sanofi Sa Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne
KR101745028B1 (ko) 2009-07-02 2017-06-08 사노피 신규 ２,３-디히드로-１ｈ-이미다조（１,２-ａ）피리미딘-５-온 유도체, 그의 제조법 및 그의 제약 용도
AR077628A1 (es) 2009-07-02 2011-09-14 Sanofi Aventis Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
PE20120640A1 (es) 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
ES2612492T3 (es) 2010-12-28 2017-05-17 Sanofi Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
EP2808322B1 (en) 2012-01-26 2017-08-23 Daiichi Sankyo Company, Limited Chromone derivative having osteogenesis promoting effect
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9371336B2 (en) 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
EP2828247B1 (en) 2012-03-23 2019-01-16 PTC Therapeutics, Inc. 4h-chromen-4-one derivatives for treating spinal muscular atrophy
ITMI20120514A1 (it) * 2012-03-29 2013-09-30 Cnr Consiglio Naz Delle Ric Erche Agente terapeutico per il trattamento dei vasi sanguigni
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2015105657A1 (en) * 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3298017B1 (en) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
US11129824B2 (en) * 2015-12-17 2021-09-28 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
US11091483B2 (en) * 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
WO2018140730A1 (en) 2017-01-27 2018-08-02 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CN109748914B (zh) * 2018-12-29 2021-05-25 上海珂臻医药科技有限公司 吡啶并嘧啶类化合物及其应用
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3090315C (en) 2019-05-15 2023-09-19 Biokine Therapeutics Ltd. 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CN111533721B (zh) * 2020-05-15 2022-04-26 浙江大学 苯并吡喃酮或喹啉酮类化合物及其应用
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN117615763A (zh) * 2021-02-01 2024-02-27 健道生物医药有限公司 磷酸肌醇3激酶β抑制剂及其组合物和制备方法
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
AU2024406047A1 (en) * 2023-12-19 2026-07-16 Merck Sharp & Dohme Llc Agonists of trem2 activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604170A (ja) * 1983-06-21 1985-01-10 Nippon Shinyaku Co Ltd キノロン誘導体
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
EP0459983A1 (en) * 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE158288T1 (de) 1990-06-20 1997-10-15 Upjohn Co Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate

Also Published As

Publication number Publication date
PT1257537E (pt) 2007-08-03
DE60128655T2 (de) 2008-02-07
JP4820518B2 (ja) 2011-11-24
US6977255B2 (en) 2005-12-20
DK1257537T3 (da) 2007-10-01
JP2003530318A (ja) 2003-10-14
CY1108023T1 (el) 2013-09-04
DE60128655D1 (de) 2007-07-12
US20080312233A1 (en) 2008-12-18
EP1857443A2 (en) 2007-11-21
EP1857443B1 (en) 2012-03-28
CN1263743C (zh) 2006-07-12
HK1115378A1 (en) 2008-11-28
HK1051187A1 (en) 2003-07-25
US20080206312A1 (en) 2008-08-28
AU3042601A (en) 2001-07-31
EP1257537A4 (en) 2003-04-23
US7405211B2 (en) 2008-07-29
US20030216389A1 (en) 2003-11-20
EP1857443A3 (en) 2007-12-26
AU2001230426B2 (en) 2005-12-01
CN1891699A (zh) 2007-01-10
CA2398163A1 (en) 2001-07-26
EP1257537A1 (en) 2002-11-20
CN1891693A (zh) 2007-01-10
CN1418195A (zh) 2003-05-14
NZ520300A (en) 2004-05-28
US20050085471A1 (en) 2005-04-21
ATE551325T1 (de) 2012-04-15
ES2286093T3 (es) 2007-12-01
ATE363471T1 (de) 2007-06-15
WO2001053266A1 (en) 2001-07-26
EP1257537B1 (en) 2007-05-30
AU2001230426C1 (en) 2006-06-22
US7572791B2 (en) 2009-08-11

Similar Documents

Publication Publication Date Title
EP1257537B1 (en) Therapeutic morpholino-substituted compounds
CA2495661C (en) Inhibition of phosphoinositide 3-kinase beta
AU2016200569A1 (en) Novel 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5- disubstituted -3H-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
KR20100118977A (ko) 거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026
PH12014502166B1 (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
CN105153190B (zh) 含联芳基酰胺结构的杂环并嘧啶类化合物及其制备方法和应用
CN101260104A (zh) 抑制磷酸肌醇3-激酶β
EP1541149A1 (en) Phosphodiesterase inhibitor
JPH03500542A (ja) 新規な化合物及び治療法
HK1051187B (en) Therapeutic morpholino-substituted compounds
JP7516365B2 (ja) 新規化合物
HK1115378B (en) Therapeutic morpholino-substituted compounds
AU2003260916B2 (en) Inhibition of phosphoinositide 3-kinase-beta
CN121226305A (zh) 一类7-羟基-3-(2-羟基苯基)-2h-色烯-2-酮类pde2抑制剂及其应用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150126